Roche Early-Stage Hep C Candidates Show Promise At AASLD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As Roche aims to maintain a strong position in the hepatitis C market amid the emergence of new treatment mechanisms, the company is seeking to move forward clinical-stage polymerase and protease inhibitors in development.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.